Table 1.
The European LeukemiaNet Standardized Reporting System for risk stratification of acute myeloid leukemia based on cytogenetics and molecular testing1
| Risk category | Cytogenetic abnormalities | Molecular abnormalities |
| Favorable risk | t(15;17) inv(16)/t(16;16)2t(8;21)2 | CN-AML with biallelic CEBPA mutationCN-AML with NPM1 mutated but FLT3-ITD negative |
| Intermediate risk | CN-AMLt(9;11)All others abnormalities not classified as favorable or adverse risk | CN-AML with:NPM1 mutated/FLT3-ITD positiveNPM1 wild type/FLT3-ITD negativet(8;21)/inv (16) with c-KIT mutation |
| Adverse risk | inv (3)/t(3;3) | CN-AML with FLT3-ITD positive |
| t(6;9) | ||
| t(v;11)/MLL rearranged | ||
| - 5/-5q | ||
| -7 | ||
| Monosomal karyotype | ||
| Abnormal 17p | ||
| Complex cytogenetics |
1Table modified from Mrózek et al[24];
2
The good prognosis of inv(16) and t(8;21) is maintained even with additional cytogenetic abnormalities. The presence of concomitant c-KIT mutation may increase relapse risk in t(8;21) and to lesser extend inv(16). CN-AML: Cytogenetically normal acute myeloid leukemia; CEBPA: CCAAT enhancer binding protein alpha; FLT3-ITD: FMS-like tyrosine kinase 3 gene-internal tandem duplication; MLL: Mixed lineage leukemia; NPM: Nucleophosmin.